Search Results

You are looking at 1 - 5 of 5 items for :

  • "colchicine" x
  • Chemistry and Chemical Engineering x
  • Refine by Access: All Content x
Clear All

The Merck Index, 14th edn, monograph 2470 for colchicine, p. 414. S. Sweetman (ed.), Martindale, The Complete Drug Reference, 33rd edn, 2002, p. 400

Full access

Abstract  

This work reports the synthesis, radiolabeling and preliminary biodistribution results in tumor-bearing mice of the 99mTc(CO)3–AOPA colchicine conjugate. The novel ligand was successfully synthesized by conjugation of N-(acetyloxy)-2-picolylamino (AOPA) to deacetylcolchicine via a short carbonyl-methylene linker. Radiolabeling was performed in high yield with [99mTc(CO)3]+ core. 99mTc(CO)3–AOPA colchicine conjugate was hydrophilic and was stable at room temperature. Biodistribution studies in tumor-bearing mice showed that 99mTc(CO)3–AOPA colchicine conjugate accumulated in the tumor with good uptake and retention. However, its clearance from normal organs was not so fast, resulting in poor T/NT ratios. Further modification on the linker or/and 99mTc-chelate to improve the tumor targeting efficacy and in vivo kinetic profiles is currently in progress.

Full access

Abstract  

This work reports the synthesis and preliminary biodistribution results of [131I]SIB-PEG4-CHC in tumor-bearing mice. The tributylstannyl precursor ATE-PEG4-CHC was synthesized by conjugation of ATE to amino pegylated colchicine NH2-PEG4-CHC. [131I]SIB-PEG4-CHC was radiosynthesized by electrophilic destannylation of the precursor with a yield of ~44%. The radiochemical purity (RCP) appeared to be >95% by a Sep-Pak cartridge purification. [131I]SIB-PEG4-CHC was lipophilic and was stable at room temperature. Biodistribution studies in tumor-bearing mice showed that [131I]SIB-PEG4-CHC cleared from background rapidly, and didn’t deiodinate in vivo. However, the poor tumor localization excluded it from further investigations as a tumor-targeted radiopharmaceuticals.

Full access

)propan-2-yl]phenol), degradation. The presence of colchicines (N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl] acetamide) and its derivative (N-acetil colchinol methyl ether) was identified that is the most used alkaloid

Full access

. Narciclasine does not affect the activity of proteases in vitro, but inhibits the synthesis of proteases at the ribosome level. Narciclasine is described as an anti-mitotic substance similar to colchicine. Narciclasine is also an inhibitor of peptide bond

Open access